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Metabolic and Kinetic analyses of influenza
production in perfusion HEK293 cell culture
Emma Petiot1,2, Danielle Jacob1, Stephane Lanthier1, Verena Lohr3, Sven Ansorge1 and Amine A Kamen1,2*
Abstract
Background: Cell culture-based production of influenza vaccine remains an attractive alternative to egg-based
production. Short response time and high production yields are the key success factors for the broader adoption
of cell culture technology for industrial manufacturing of pandemic and seasonal influenza vaccines. Recently,
HEK293SF cells have been successfully used to produce influenza viruses, achieving hemagglutinin (HA) and
infectious viral particle (IVP) titers in the highest ranges reported to date. In the same study, it was suggested that
beyond 4 × 106 cells/mL, viral production was limited by a lack of nutrients or an accumulation of toxic products.
Results: To further improve viral titers at high cell densities, perfusion culture mode was evaluated. Productivities
of both perfusion and batch culture modes were compared at an infection cell density of 6 × 106 cells/mL. The
metabolism, including glycolysis, glutaminolysis and amino acids utilization as well as physiological indicators such
as viability and apoptosis were extensively documented for the two modes of culture before and after viral
infection to identify potential metabolic limitations. A 3 L bioreactor with a perfusion rate of 0.5 vol/day allowed us
to reach maximal titers of 3.3 × 1011 IVP/mL and 4.0 logHA units/mL, corresponding to a total production of 1.0 ×
1015 IVP and 7.8 logHA units after 3 days post-infection. Overall, perfusion mode titers were higher by almost one
order of magnitude over the batch culture mode of production. This improvement was associated with an
activation of the cell metabolism as seen by a 1.5-fold and 4-fold higher consumption rates of glucose and
glutamine respectively. A shift in the viral production kinetics was also observed leading to an accumulation of
more viable cells with a higher specific production and causing an increase in the total volumetric production of
infectious influenza particles.
Conclusions: These results confirm that the HEK293SF cell is an excellent substrate for high yield production of
influenza virus. Furthermore, there is great potential in further improving the production yields through better
control of the cell culture environment and viral production kinetics. Once accomplished, this cell line can be
promoted as an industrial platform for cost-effective manufacturing of the influenza seasonal vaccine as well as for
periods of peak demand during pandemics.
Background
In the last few years, the increasing risk of a pandemic
influenza outbreak has brought into question the reac-
tivity and efficiency of the present flu vaccine produc-
tion mode. The current egg-based processes present
different drawbacks, such as the minimum period of six
months required after the selection of the flu strain to
generate a sufficient supply of the vaccines. Conse-
quently, pharmaceutical companies involved in influenza
vaccine manufacturing are evaluating, among other
expression systems, the cell-based mode of production
as an attractive alternative to the hen’s egg processes.
Cell-based production processes are presently well-
established technology platforms for manufacturing bio-
pharmaceuticals, offer multiple advantages such as flex-
ibility, expandability, and eventually shorter lead time.
Several cell-based processes using adherent cell lines,
such as Vero or MDCK cells, for the production of
influenza or other viral pathogens, are already well-
documented [1-7]. However, adherent cell culture pro-
cesses remain limited in cell density, due to microcarrier
surface saturation. Also, they are mostly performed with
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serum-containing media [5]. Recently, new influenza
production processes were proposed with suspension
cell lines. Contrary to adherent cell cultures, suspension
cell cultures have the potential to be operated at high
cell densities and thus can thus achieve higher virus
titers [5]. MDCK cells, which are the most popular cells
used for influenza virus replication, were therefore
adapted to suspension culture, resulting in a 1 logHA/
mL increase of influenza titers over microcarrier MDCK
cultures [4,8]. Other suspension growing cell lines,
including duck AGE1.CR cells [9], human PER.C6 cells
[10] or the avian embryonic derived stem cells EB14
(chicken) and EB66 (duck) [11], have been evaluated for
infection and production of the different A and B influ-
enza strains.
Previous work from our group demonstrated that the
HEK293SF suspension cells are a valuable alternative for
influenza production [12]. A scalable batch production
process has been established producing 2.81 × 109 IVP/
mL (IVP: infectious viral particles) and 4.01 log HA
units/mL, values in the same range as the results
obtained from MDCK or Vero cells [5,12]. Infection
parameters, such as trypsin concentration and MOI
(multiplicity of infection), were optimized to achieve
high yields, but a leveling off of the maximal HA and
infectious viral particles was observed at cell densities of
infection higher than 4 × 106 cells/mL [12]. Although
HEK293SF cells could grow in the selected serum-free
medium to a maximal cell density of 10 × 106 cells/mL
in batch mode [12], viral production appeared limited at
a lower cell density. This so called “cell density effect” is
consistent with observations previously reported by our
group for other virus productions in HEK293SF cells.
As for adenovirus production with this cell line, the lim-
itations in viral productivity beyond a critical cell density
could be related to either nutrient limitations or inhibit-
ing by-product concentrations [13,14]. To alleviate these
limitations as in the case of adenovirus production, dif-
ferent feeding strategies based on medium exchange
[13], fed-batch mode [15,16] or perfusion strategies [17]
have been explored.
Medium exchange is often used for viral productions
despite the fact that this procedure is not easily scalable.
For large-scale productions, the fed-batch strategy is the
most convenient way to increase the cell density and
alleviate nutrient limitations. However, extensive meta-
bolic analyses are required to define an appropriate feed.
In early stages of development, the perfusion strategy,
although equipment and operation intensive, remains a
valuable approach to alleviate metabolic limitations and
reduce the residence time of the viral particles in the
culture environment. Through continuous feeding of the
medium, perfusion culture supplies cells with fresh
nutrients and limits the accumulation of toxic by-
products by dilution. Simultaneously, the viral particles
produced are harvested in the perfused supernatant,
thus avoiding a possible loss of functionality of the viral
particles.
In the present study, a perfusion culture of HEK293SF
cells was evaluated for high yield productions of a func-
tional influenza virus. The primary objective of this
work was to investigate if infection at high cell densities
combined with a constant supply of fresh medium
would increase the production yield. In addition, our
secondary goal was to continuously harvest the influenza
virus from the cell supernatant to minimize its residence
time in the bioreactor and to maintain high infectious
virus titer levels over the course of the production.
Overall, the results led to a better understanding of the
influenza virus production kinetics by HEK293SF cells
under controlled culture conditions.
Results & Discussion
The perfusion culture was compared to a batch culture
in order to determine the differences if any in cell
growth, and viability or in the metabolic pattern of
HEK293SF cells due to continuous feeding of fresh
medium. For both modes of operation the cultures were
infected at a cell density of 6 × 106 cells/mL. This target
cell density is generally in the late growth phase of
HEK293SF cell batch culture. First, the study focused on
analyzing the effects of the perfusion on the physiologi-
cal state of the cell pre- and post-infection, and second,
on establishing its impact on production yields once
infected by an influenza H1N1 strain.
Comparison of non infected batch and perfusion HEK293
cells cultures
Cell growth and death pattern
As expected, when perfusion was started after two days
of culture at an exchange rate of 0.5 vol/day, the maxi-
mal cell density was significantly increased. Cell growth
was maintained for 9 days, attaining a viable cell density
of 15 × 106 cells/mL. In contrast, cell growth stopped in
the batch system after 8 days of culture at a maximal
cell density of 8.3 × 106 cells/mL (Figure 1A-B). Also,
the specific growth rate, μ, was slightly higher in the
perfusion system (0.024 h-1 vs 0.021 h-1 for batch cul-
ture) (Table 1).
A higher cell viability was observed for the perfusion
culture at the targeted infection cell density (85% in per-
fusion vs 60% in batch culture) (Figure 2). The apoptotic
cell population was 23% lower in the perfusion culture
than in the batch culture accounting for the higher cell
viability in the perfusion culture. This observation is
consistent with previously published results relating
apoptosis to nutrient deprivation in cell cultures. For
example, glucose or amino acid depletion have been
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related to the high rate of death in hybridoma cells.
Also, depletion of growth factors or cytokines could also
have a strong impact on cell death [18]. On the other
hand, necrosis is generally described as occurring
because of physical stresses or accumulation of high
levels of toxic by-products, such as lactate or ammo-
nium [19]. Consequently, the fact that perfusion pro-
vides fresh nutrients while clearing part of the toxic by-
products in spent medium contribute in maintaining a
high viable HEK293SF cell population in the culture.
HEK293SF cell metabolism
Metabolic and apoptotic pathways are strongly related
as they converge on a shared set of proteins, as for
example the GLUT transporter family or glycolytic
hexokinase [20]. So, the metabolic states of the
HEK293SF cells were evaluated and compared under
batch and perfusion culture conditions in order to
identify any potential changes in the physiological state
of the cells pre-infection which in turn might impact
the production capacity of the cells. Only the central
metabolic pathways (glycolysis, glutaminolysis and
amino acid pathways) were analyzed taking into
account consumption and production of major carbon
substrates and by-products. For consistency, the com-
parison of HEK293SF cell metabolism in perfusion ver-
sus batch culture was done between 50 h to 168 h,
time periods corresponding to the exponential phase
for both cultures once culture feeding was started for
the perfusion culture. The global uptake and produc-
tion per cells are presented in Table 1.
Figure 1 Comparison of batch (A, C) and perfusion (B, D) culture processes for cell growth (A, B) and influenza production (C, D).
Viable (black circles), dead (up grey triangles), and total (grey diamonds) cell densities were plotted with viability (dashed lines) and HA titers (grey
bars) over time. The perfusion was started at 48 h of culture.
Table 1 Impact of feeding mode, batch or perfusion, and of influenza infection on HEK293SF cell growth and
metabolism
Standard
deviation
Batch
culture
Infected batch culture Perfusion
culture
Infected perfusion culture
pre-infection post-infection pre-infection post-infection
μmax, h
-1 10% 0.021 0.02 -0.013 0.024 0.023 0.019
YGlc/X, mmol.10
-6cell 17% 0.023 0.023 0.026 0.056 0.057 0.038
YLact/X, mmol.10
-6cell 22% 0.012 0.014 0.01 0.088 0.083 0.037
YGln/X, mmol.10
-6cell 10% 0.007 0.007 0.001 0.018 0.014 0.01
YAmm/X, mmol.10
-6cell 43% 0.001 0.001 0.002 0.003 0.003 0.009
YLact/Glc, mol.mol
-1 19% 0.5 0.6 0.4 1.6 1.5 1.0
YAmm/Gln, mol.mol
-1 43% 0.1 0.1 2.0 0.2 0.3 1.1
The values presented in bold letters correspond to culture phases with infection with A/PR/8/34 influenza strain.
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Glycolysis & Glutaminolysis In the batch culture, the
two major carbon substrates, glucose and glutamine,
were not limiting nutrients since their concentrations at
the end of the culture were of 7 mM and 0.54 mM
respectively (corresponding to 21% and 13.5% of their
initial concentrations). The maximum glucose and gluta-
mine uptake rates in the batch culture were very close
to the values previously reported in batch cultures of
HEK293SF cells, with a νGlc max of 0.13 mmol.h
-1.10-
9cell and a νGln max of 0.01 mmol.h
-1.10-9cell [21-24]. In
comparison with MDCK and Vero cells, the HEK293SF
specific consumption rates were 5 to 7 times lower than
those of MDCK cells (νGlc max of 0.75 mmol.h
-1.10-9cell)
[25] and Vero cells (νGlc max 0.5 mmol.h
-1.10-9cell) [26].
As previously reported, the two major metabolic by-pro-
ducts, lactate and ammonium ions, could be responsible
for cell death [27]. However, under the culture conditions
described herein, their concentrations never reached the
toxic limits (20 mM for lactate and 3 mM for ammonia)
described for other cell lines [27-30]. Their final concen-
trations were 9.9 mM and 1.7 mM, respectively, and their
maximal production rates were of 0.15 mmol.h-1.10-9 cell
for πLact and of 0.01 mmol.h
-1.10-9 cell for πAmm. These
values are similar to the results obtained in other studies
for HEK293 cells [21,23]. Interestingly, HEK293SF cells
cultivated in HYQSFM TransFx medium appear to have a
more efficient glycolytic metabolism in batch culture than
MDCK or Vero cell lines, as the molar ratio YLact/Glc are 3
times lower than for these cell lines (0.5 vs 1.7 for Vero
cells and vs 2.0 for MDCK cells [25,26]). These cell line
metabolic characteristics will be further discussed in the
section addressing the viral production aspect.
A direct impact of culture perfusion mode was observed
on the glycolysis and glutaminolysis of HEK293SF cells.
They consumed at least twice the amount of glucose and
glutamine per cell as compared to the same phase in the
batch culture (Table 1), leading to a depletion of glucose
at the end of the perfusion culture. The differences
between the two modes of culture are even more drastic
regarding the specific by-product production rates. A 7-
fold increase was observed for πLact while the specific
ammonia production, πAmm was enhanced of 3-fold
(Table 1). These results are consistent with previous data
obtained with the same cell line under similar operating
conditions (0.5 vol/day perfusion rate) [17]. The molar
ratios for YLact/Glc (1.6) and YAmm/Gln (0.2) measured in
this study also confirmed the ones previously obtained by
Henry et al. [17] (1.6 and 0.4, respectively) and were also
higher in comparison to the batch culture.
Amino acid metabolism With the exception of aspartate,
which was consumed at over 93% of its initial concentra-
tion in the batch culture, no clear amino acid limitations
were observed for both the batch and perfusion cultures.
In the perfusion culture, the final concentration of aspar-
tate was 1.02 mM, a value 10 times higher than the final
concentration in the batch culture. Consistent with pre-
vious reports on HEK293SF cell metabolism, aspartate and
serine were the most-consumed amino acids. Aspartate as
well as glutamate and serine, have already been described
as limiting amino acids for HEK293SF cells cultivated in
fed-batch mode [31]. Even so, we should note that, at the
targeted cell density of infection (6 × 106 cells/mL), the
aspartate concentration was 30% higher than its initial
concentration. Thus, no amino acids were considered to
be limiting at the time of infection or during the cell
growth, either for the batch or the perfusion culture sys-
tem. Glycine, alanine and cysteine, which could also be
described as by-products of cell cultures, were the only
amino acids to be released as reported for HEK293SF cells
and other cell lines [26,32,33].
These comparative analyses support the conclusion
that the HEK293 SF metabolic state is more active in the
perfusion culture conditions. However, the quantification
of key metabolites did not allow us to identify clear lim-
itations or inhibitions that could account for the decrease
in cell viability in the batch culture. It is likely that other
Figure 2 Cell death pattern comparison for infected cultures
(Batch A; Perfusion B). Viable (black circles), necrotic (up grey
triangles) and apoptotic (down grey triangles) cell populations are
presented. The perfusion was started at 48 h of culture.
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molecules not quantified in the present study might be
limiting the culture and inducing cell apoptosis in the
batch culture [18].
Influenza production during batch and perfusion culture
In order to assess whether the perfusion mode of opera-
tion could overcome the leveling off of influenza produc-
tion observed in our previous study for cell densities at
infection higher than 4 × 106 cells/mL [12], cell cultures
were infected at a target cell density of 6 × 106 cells/mL.
Influenza production levels were thus monitored and the
cell growth and death pattern as well as the metabolic
state of the HEK293SF cells were compared in batch and
perfusion cultures.
Cell growth and death pattern
Based on cell growth profiles only, the kinetics of the
batch culture infected at 6 × 106 cells/mL were similar to
the previous infection performed at 4 × 106 cells/mL by
Le Ru et al., (2010) [12] (Figure 1-C). Cell growth arrest
was observed after infection, and cell viability remained
high for 24 hpi (hours post-infection). In contrast, the
cell density in the perfusion culture after infection
increased by 60% within 24 h, attaining 10 × 106 cells/mL
(Figure 1 &2).
Influenza infection had an impact on the cell death
pattern in both cultures. Cell apoptosis and necrosis
were stopped for 24 hpi, then cell death increased dra-
matically during the next 48 h (Figure 2). This reduction
of cell death right after infection with influenza viruses
was also observed for AGE1.CR cells that were culti-
vated in Wave reactors [9]. A 24 h delay before an
increase in cell death was also described for adherent
MDCK cells infected with the A/PR/8/34 strain; how-
ever, the effect of the infection kinetics on cell viability
appears to be highly dependent on the viral strain [34].
The mechanisms involved in apoptotic cell death due
to influenza infection and the resulting production
kinetics still remain only partially understood. Many stu-
dies concluded that influenza viruses induce apoptosis
and provoke cell lysis, depending on the cell line studied.
The time of occurrence of these events might vary
between 10 to 40 hpi [35-37]. Also, NA and NS1 influ-
enza proteins were reported to potentially regulate apop-
tosis during the viral replication cycle [35,37].
HEK293SF cell metabolism during influenza infection
To facilitate the comparison of HEK293 metabolic beha-
vior, all of the cultures were divided into two phases: the
growth phase without infection and the growth phase with
infection. For consistency, the growth phase without infec-
tion started for batch and perfusion culture at 50 h, the
starting time of the feeding in the perfusion system. It
ends when the targeted cell density for infection, was
attained (144 h for the batch culture and 120 h for the
perfusion culture). Then, for both cultures, the growth
phase with infection was reduced to 24 hpi, as this time
period corresponds to the virus production phase before
the inception of massive cell death (Figure 1C-D). This
time period corresponds to the time between 144 and 168
h for the batch culture and between 120 and 144 h for the
perfusion culture.
Glycolysis & Glutaminolysis Consistent with observa-
tions made in non-infected cultures, the metabolic activ-
ity was higher in the perfusion than in the batch culture,
both before and after influenza infection. For example,
between the batch and perfusion growth phase with
infection, YGlc/x increased by 30% and YLact/x and YAmm/x
were 4 times higher (Table 1). Nevertheless, the increase
of metabolic activity in perfusion compared to batch cul-
ture remains less pronounced in the infection phase than
in the growth phase.
Furthermore, when comparing the cell metabolism
before and after influenza infection, a decrease in lactate
production accompanied by a constant or a slight
decrease in specific glucose consumption was observed.
Although this pattern has been already described in the
case of MDCK cells infected with a H3N8 strain [38],
this metabolic trend is not common. Other studies of the
same group, performed with MDCK cells either in 5-L
bioreactor [7] or in 6-well plate [39], has demonstrated a
clear increase of the glycolytic pathway activity after 12
hpi. For these cases, the authors concluded that meta-
bolic changes for MDCK cells undergoing influenza
replication are to a lesser extent related to the virus repli-
cation itself, but rather specific to apoptosis inception
occuring at the same time [39]. Interestingly, the meta-
bolic behavior of MDCK cells seems to be dependent on
the MOI employed. A reduction in glycolytic activity was
observed for infection at low MOI [38] whereas high gly-
colytic behavior was observed for infections at high MOI
[7,39]. In this context, it should be kept in mind that the
HEK293 cell present a very different metabolism than
other kidney cell lines used for influenza production such
as MDCK or Vero cells. This is supported by differences
in glucose consumption rates during normal growth
without infection (see earlier section). It is thus very
likely that the glycolytic response to influenza replication
is cell line dependent.
In the case of HEK293SF cells, the molar ratio of YLact/
Glc decreased by about 30% in both batch and perfused
cultures after infection. Apparently, during the short
growth phase from infection until 24 hpi, HEK293SF cells
were using glucose more efficiently, with a larger part of
this substrate being used either for growth or for viral pro-
duction. By comparing these results with other viral pro-
ductions in HEK293SF cells, it can be concluded that this
metabolic behavior is specific to the virus produced: for
example, in the case of adenovirus productions on
HEK293SF cells in the perfusion system, the YLact/Glc ratio
was increased by 12% [17].
Petiot et al. BMC Biotechnology 2011, 11:84
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With respect to the glutaminolysis pathway and the
generation of ammonia, it is noticeable that for both
infected cultures, the YAmm/Gln ratio increased signifi-
cantly after infection (batch 20-fold, perfusion 4-fold).
This major increase for the batch culture is mainly due
to an important decrease in the specific glutamine con-
sumption (YGln/x), also corresponding to the growth
phase plateau of the culture. It seems that the
HEK293SF glutaminolysis metabolism is not favourable
for virus multiplication as more ammonia was produced
in both cultures. In fact, concentrations as low as 1 mM
of ammonia can induce a reduction of 50% of the A/
PR/8 strain production [39,40]. Indeed, ammonia is
thought to be acting on virus intralysosomal pH, and
therefore potentially affects the lysosome-dependent
stage of the influenza infection process [40].
Amino acids According to Sidorenko & Reichl [40,41],
the intracellular pool of free amino acids could be a
possible bottleneck for virus productions, as high virus
yields require the uptake and synthesis of additional
resources during the infection process. In our case, with
a total initial amino acid concentration of 48 mM, the
free amino acid content of our media is significantly
higher than the usual amino acid content of serum-free
media used for influenza productions (30.3 mM for Ex-
Cell MDCK medium [4], 21.8 mM for SMIF8 medium
and 16.2 mM for Episerf [9]). Therefore, it is not sur-
prising that the amino acids quantification did not
demonstrate any limitations at the time of infection for
either the batch or the perfusion cultures. In addition,
no limitations of amino acids were found during the 24
hpi growth phase.
In the batch culture, most of the free amino acid con-
centrations increased or presented a very low specific
uptake over that period (Table 2). Only five amino acids
presented an uptake higher than 5% of their initial concen-
trations (glutamine, histidine, proline, valine and methio-
nine) with a maximal uptake for glutamine (15.3% of its
initial medium content). In the perfusion culture, meta-
bolic activity seemed to be increased compared to the
batch culture, as most of the amino acids were consumed
at higher rates (Table 2). Glutamine was also among the
most highly consumed amino acid in the perfusion system
(36% of its initial concentration) along with cysteine (48%),
leucine (23%), lysine (21%) and arginine (22%). After 24
hpi, a massive release of amino acids is observed in both
batch and perfusion cultures, which is certainly linked to
cell lysis provoked by virus production.
Overall, the differences observed between batch and
perfusion amino acid uptake and release did not demon-
strate a specific pattern for amino acid metabolism dur-
ing influenza production. Secondly, if the free amino
acid pool is in excess compared to the cell’s require-
ments for virus synthesis, the only element impacting
the amino acid uptake and release is the metabolic
activity of the cell. This observation also leads to the
hypothesis that any potential limitation and/or inhibi-
tion during the batch culture, leading to a leveling in
viral production observed in previous studies with
HEK293 cells [12], was due to other non-quantified
components in the culture medium.
Production of Influenza virus A/PR/8/34
Quantification of the total (HA titers) and infectious
(TCID50 titers) influenza particles are presented in Fig-
ure 3, table 3 and 4 for both perfusion and batch mode.
TCID50 detection technique For the TCID50 titrations,
two detection techniques were evaluated and compared
in terms of sensitivity and precision. Infected MDCK
cell plates were evaluated by microscopy either, with [8]
or without immunostaining with antibodies [42]. Detec-
tion by immunostaining was clearly more sensitive pro-
viding results with a 0.8 log IVP/mL higher titer than
the classical microscopic detection technique. A com-
parison of the results from these two techniques clearly
raises the question of the difficulty of comparing influ-
enza viral titers reported in different studies and shows
that quantification techniques should be identical to
allow sound comparisons. One should carefully and cri-
tically evaluate the methods used for titer quantification
before drawing conclusions about yields from the pub-
lished studies. In this study, immunostaining results will
be used for comparison with titers obtained in other
studies as this detection method is most commonly
employed for TCID50 assays [7,8].
Table 2 Free amino acid uptake and release during HEK293SF cell growth after infection
Gln Asp Glu Ser Asn Gly His Thr Arg Ala Pro Cys Val Met Ile Leu Lys Phe
Free amino acid level
before cell infection, mM
Batch 2.21 1.10 1.62 5.84 7.95 0.66 0.98 2.87 1.78 1.01 4.36 0.43 2.50 0.80 2.31 3.57 2.66 1.14
Perfusion 1.77 0.87 1.48 2.80 7.06 0.73 0.87 2.17 1.32 1.28 3.70 0.02 2.04 0.67 1.91 3.11 2.17 0.96
Specific uptake or release
of free amino acids,
μmol.10-6 cell
Batch 0.09 0.00 -0.03 0.01 -0.06 -0.03 0.01 -0.05 0.01 -0.09 0.05 -0.04 0.03 0.01 0.01 -0.01 -0.03 -0.01
Perfusion 0.12 0.02 -0.01 0.08 0.00 -0.06 0.01 0.03 0.04 -0.08 0.00 0.02 0.03 0.01 0.05 0.09 0.06 0.01
Values for specific uptake and release were calculated between infection time and the start of cell death (24 h post-infection). Positive values represent amino
acid uptake, while negative ones represent their release.
Petiot et al. BMC Biotechnology 2011, 11:84
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Viral production In batch mode, the production
kinetics of influenza viruses were very similar to the one
observed in previous cultures performed with HEK293
cells [12] or with other adherent cell lines [7,8]. Both
HA and TCID50 titers reached a maximal value after 24
hpi, before the start of cell death (Figure 1-C). A maxi-
mal total particle titer of 3.7 logHA units/mL and a
maximal infectious particle titer of 5.3 × 1010 IVP/mL
were obtained at 2 days post-infection (dpi). The total
productivity obtained in our 3 L working volume bior-
eactor was 1.6 × 1014 infectious influenza particles cor-
responding to 7.2 logHA units (Table 3 & 4). In
comparison, these results are clearly among the highest
values reported in the literature for cell lines such as
MDCK, Vero and PER.C6 cells.
Using perfusion mode at a rate of 0.5 vol/day after 48 h
of batch culture, allowed a 10-fold increase of the pro-
duction titers in terms of infectious viral particles.
Indeed, the maximal titer obtained was 3.3 × 1011 IVP/
mL at 3 dpi in perfusion mode versus 5.3 × 1010 IVP/mL
at 2 dpi in the batch mode (Table 4). The increase was
less obvious for HA titers, with a 0.6 logHA units/mL
increase in perfusion mode (Table 3). The maximal total
productivity in the perfusion cultivation, which takes into
account the harvest of spent medium (corresponding to
9 L volume in total), was of 1.0 × 1015 IVP and of 7.8
logHA units. This corresponds to a production increase
of 8.4 × 1014 IVP and 4.8 × 107 HA units compared to
the batch culture. The significant increase in virus yield
could first be attributed to the increase in cell density
after infection in the perfusion system (Figure 1C-D).
Cell growth was maintained for approximately 32 hpi in
this system, reaching a cell density of 10 × 106 cell/mL.
So, in comparison to the batch culture at 48 hpi, 4 × 106
additional viable cell producers per mLcontributed to the
accumulation of viral particles in the culture.
Perfusion also allowed us to maintain or increase the
specific productivity of the cells as compared to the batch
mode at 2 dpi (Table 3 & 4). Thus, at 3 dpi, HEK293SF
cells under perfusion mode had a 4-fold higher specific
productivity in terms of influenza infectious particles
than cells infected in the batch culture mode. This could
be attributed to the maintenance of a higher viability and
better physiological state of the cells, as explained earlier,
by providing fresh medium and removal of potential inhi-
bitors during perfusion.
Furthermore, the daily harvesting of virions in the per-
fusion system was also a means of preventing further
degradation of the particles and thus maintaining a
higher productivity. It should be underlined that the total
particle titers (logHA units) were more stable than the
infectious particle titers (IVP) after 2 dpi, as influenza
infection viral particles show a 2-log decrease after attain-
ing their maximal values either in batch or perfusion cul-
ture. Degradation of infectious influenza particles in
HEK293SF cell culture supernatant has already been
observed in the study of Le Ru et al. (2010). [12]. This
decrease might be explained by the exposure of the virus
to the culture temperature or to proteases released in the
culture supernatant upon cell lysis over time. The
Figure 3 Influenza production for batch (A) and perfusion (B)
cultures. Viable cells (black circles) were plotted with HA (grey bars)
and TCID50 titers (up grey triangles) over time. The perfusion was
started at 48 h of culture.
Table 3 Influenza HA production in batch and perfusion culture at different days post-infection (dpi)
HA titers, logHA units/mL Total productivity, logHA units Specific productivity, HA units/105 cell
1 dpi 2 dpi 3 dpi 4 dpi 1 dpi 2 dpi 3 dpi 4 dpi 1 dpi 2 dpi 3 dpi 4 dpi
BATCH 2.5 3.7 3.4 6.0 7.2 6.9 6 97 49
PERFUSION 1.9 4.3 4.0 3.8 5.4 7.8 7.8 7.7 0.9 199 191 173
Total viral particles were quantified by hemaglutination assays (HA titers). Total productivity was calculated at different times of harvest post-infection (Harvest of
the perfused flow, 1.5 L/day, was taken into account in the calculation for perfusion system). Specific productivities were calculated based on total productivity and
the maximum cell density attained (5.76 × 106 cell/mL in batch and 10.1 × 106 cell/mL in the perfusion system).
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susceptibility of influenza viruses to temperature has
already been demonstrated as strain-specific [43] and the
A/PR/8/34 influenza strain was shown to be unstable at
50°C [44]. But to our knowledge, no systematic studies
addressed the effects of temperature on virus stability
within broad operating ranges, and no data is available
for the range of temperature usually used for the
production.
Overall, as previously reported by Genzel et al., (2009),
it remains very difficult to compare influenza production
performances considering the wide range of cell lines,
influenza viral strains, strain variants and production
methods as well as the complexity of the cell/virus inter-
action process [5]. For example, our results from a com-
parative study showed that the production yields for an
A/PR/8/34 strain after three passages in HEK293 cells
remains 2-log lower in HEK293 as compared to MDCK
cells with infectious titers corresponding to 6.4 × 108 and
2.1 × 1010 TCID50 units/mL respectively [12]. Further-
more, Schulze-Horsel et al. (2009) reported a variation of
1 logHA units/mL for MDCK cell production of A/PR/8
variants obtained either from NIBSC or from the Robert-
Koch Institute. They concluded that A/PR/8/34 variants
could differ in replication kinetics, yields and eventually
in ratio of non-infectious to infectious particle [34]. It is
also well accepted that the various influenza strains could
have different production yields in the same cell line
[9,34,45]. In a previous study we demonstrated that var-
ious influenza strains replicate in HEK293 cells and that
the H1N1 A types (A/PR/8/34 and A/WS/33), the H3N2
A (A/Aichi/2/68 and A/HongKong/6/68) and a B type
(B/Lee/40), were produced at different yields in terms of
infectious particles and HA titers [12].
Nevertheless, compared to the data available in the cur-
rent literature, the values obtained in this study with the
perfusion culture of HEK293SF cells are among the high-
est titers obtained for cell-culture based influenza pro-
ductions and for both infectious particles (107 IVP/mL
for MDCK cells, 1010 IVP/mL for PER.C6, 109 IVP/ml
for Vero cells) and HA titers (4.0 logHA units/mL for
MDCK cells, 4.3 logHA units/ml for PER.C6, 4.0 logHA
units/mL for Vero cells) [5]. These values confirm that a
HEK293SF cell platform is an excellent alternative for the
production of influenza virus compared other cell line
platforms, but more importantly, underline the potential
in further improving the production yield to optimize the
cost-effectiveness and meet surge capacity criteria.
Stability study of influenza viral particles in
HEK293SF cultures A stability study was performed to
confirm the assumption that perfusion with continual
harvest and storage of the production at 4°C allows for
a better conservation of the viral particles. Culture
supernatants were collected at 2 dpi, for two viral pro-
ductions performed either at 35°C or 37°C. Samples
were then stored either at 2-8°C or kept at the produc-
tion temperature set point. Results from these experi-
ments confirmed that the total HA content was stable,
indicating that the physical (or total) influenza viral par-
ticles number was maintained whatever the temperature
of storage applied (Figure 4-A). The variations in HA
titer observed were lower than the HA assay standard
error (0.18 logHA units/mL). In contrast, infectious par-
ticles were more affected by storage at high temperature
(35°C and 37°C), as a 2-log and a 4-log decrease were
observed after 48 h of storage at 35°C and 37°C, respec-
tively (Figure 4-B). Storage at 2-8°C for productions per-
formed at 37°C did not significantly reduce viral particle
degradation as a 3-log decrease was still observed. In
contrast, for the productions performed at 35°C, storage
at 2-8°C reduced the degradation of infectious particles
by 1-log. Overall, these results confirm that operating
the production at a temperature of 35°C and continu-
ously harvesting the supernatants for subsequent storage
at 2-8°C significantly contribute increasing the viral
titers and the final yield and justify the perfusion pro-
duction strategy used in this study.
Conclusions
The perfusion system is a powerful means to observe
the impact of HEK293SF cell metabolism on the influ-
enza infection process and production kinetics. The
objectives were to identify if the cell density effect
observed beyond 4 × 106 cells/mL could be overcome
by providing a constant supply of nutrients to the cell
and eliminating toxic elements from the culture super-
natant. This study demonstrates that a significant
increase of total and infectious viral particles can be
achieved with a perfusion rate of 0.5 vol/day, leading to
Table 4 Influenza infectious particle production in batch and perfusion cultures at different days post-infection (dpi).
TCID50 titers, TCID50 units/mL Total productivity, TCID50 units Specific productivity, TCID50 units /103
cell
1 dpi 2 dpi 3 dpi 4 dpi 1 dpi 2 dpi 3 dpi 4 dpi 1 dpi 2 dpi 3 dpi 4 dpi
BATCH 3.0 × 109 5.3 × 1010 3.0 × 108 1.0 × 1013 1.6 × 1014 7.9 × 1011 0.7 10.4 0.1
PERFUSION 2.0 × 109 2.1 × 1010 3.3 × 1011 2.0 × 109 7.9 × 1012 1.6 × 1014 1.0 × 1015 2.5 × 1014 0.3 4.9 36.8 8.5
Total productivity was calculated at different times of harvest post-infection (Harvest of the perfused flow, 1.5 L/day, was taken into account in the calculation for
total productivity in the perfusion system). Specific productivities were calculated based on total productivity and maximum cell density attained (5.76 × 106 cells/
mL in batch and 10.1 × 106 cells/mL in the perfusion system).
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a 4-fold increase of the viral specific cell production.
This productivity gain appears related to the sustained
cell growth and the active metabolic state of the
HEK293SF cells after infection in the perfusion culture.
Overall, this work confirmed that the HEK293SF cell
platform is an excellent alternative for the production of
influenza virus; compared to other proposed cell lines
this cell line has been very well-documented, especially
for other viral vector productions and biopharmaceuti-
cals for clinical applications. Because the titers obtained
with this cell line are among the highest reported in the
literature, this production method could increase the
cost-effectiveness and the production capacity of cell
culture-based manufacturing of influenza vaccines over
other technologies.
Methods
Cell lines and culture conditions
The HEK293SF-3F6 cell line that was used was adapted
to suspension and serum-free culture [46]. HEK293 cells
were cultivated at 37°C and 5% CO2 in the serum- and
animal-component free medium HyQSFM4-
Transfx293™ (HyClone, Waltham, MA, USA).
For TCID50 assays, adherent MDCK cells, obtained
from the American Type Culture Collection (ATCC
CCL-34, Manassas, VA), were cultivated in T75-Flasks
containing Eagle’s Minimum Essential Medium (EMEM,
ATCC) with 10% fetal bovine serum (FBS) at 37°C and
5% CO2.
Cell counts and cell population repartition
For both cell lines, viability and cell density evaluation
were performed using erythrosine B dye exclusion on a
hemacytometer, with a standard deviation of 10% on the
cell counts. Viable, apoptotic and necrotic cell popula-
tions were evaluated with the Guava Nexin kit (Guava
Technologies Inc., CA, USA) on a LSR II flow cytometer
(BD Biosciences, NJ, USA). This kit is using an annexin-
V probe to label the phosphatidyl-serines translocated
on the external face of the cell membrane during the
apoptosis process. The necrotic cells are identified with
a 7-AAD probe only able to penetrate porous cells. The
accuracy of the cell population quantifications was
determined on 3 additional flask cultures (40 mL)
infected with A/PR/8/34 at a cell density of 2 × 106
cells/mL. The maximal standard deviations for each
population during the whole culture (respectively 8.8%
for viable cells, 6.6% for necrotic cells and 7.0% for
apoptotic cells) were used for the bioreactor culture
data.
Bioreactor cultures
Bioreactor set-up
3.5-L Chemap type SG bioreactors (Mannedorf. Switzer-
land) were used for both batch and perfusion cultures.
The bioreactor set-up for batch and perfusion operations
was previously published (batch [12], perfusion [17,47]).
Bioreactors were seeded at 0.25 × 106 cells/mL in SFM4
Trans Fx293™ (HYQ) medium, and samples were taken
twice a day for subsequent analyses. The agitation rate
was set to 80-85 rpm, and the dissolved oxygen concen-
tration, pH and temperature were controlled at 40% of
air saturation, 7.1 and 37°C, respectively. An additional
system to monitor biomass through permittivity (Biomass
400) was installed on the bioreactors (Fogale Nanotech,
Nimes, France). Aeration was performed either by surface
aeration using a gas mixture of nitrogen and oxygen (gas
flow rate of 300 standard cubic centimeters per minute
(sccm)) or by sparging pure oxygen in pulse mode when
cell concentration was higher than 4 × 106 cells/mL. In
perfusion cultures, cells were grown in batch mode for
two days prior to the start of perfusion at 0.5 vol/day.
The cells were retained in the reactor with a 10-L acous-
tic filter operated in a backflush mode. The working
volume was 3-L for batch and was set at 2.7-L during the
perfusion mode of culture. Each culture was performed
once.
Figure 4 Stability of influenza total particles (A) and infectious
particles (B) at different storage temperatures. Supernatants
from infected HEK293SF cell culture were sampled at 2 dpi and
stored at 4°C or at their respective culture temperature (35°C or 37°
C) for 48 h.
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Infection of HEK-293SF cells
The A/PR/8/34 influenza virus strain (H1N1) was used
for the culture infections. The viral stock (109 IVP/mL)
was already produced in HEK293SF cells [12] and was
originally derived from a stock obtained from the Global
Bioresource Center ATCC. Cultures were infected with
influenza viruses at 6 × 106 cells/mL at an MOI of 10-3
with addition of TPCK trypsin (1 μg/mL) (Sigma, St.
Louis, MO, United States), without medium exchange
prior to the infection. During the infection phase, the
temperature was controlled at 35°C, whereas all other
parameters were controlled at standard values through-
out the whole culture, as reported in the previous study.
Metabolite quantification and metabolic parameter
calculation
Metabolites were analyzed in the culture supernatant.
Glucose, lactate and ammonia concentrations were
quantified using an IBI Biolyzer Rapid Analysis System
(Kodak, New Haven, US), with standard deviations of
7%, 12% and 33% respectively. Amino acid concentra-
tions were evaluated by HPLC using the Waters
AccQ•Tag™ method and the Waters Alliance system
(Waters, Milford, MA, US) [48]. This technique is based
on amino acid derivatization with a borate buffer and 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate at 40°
C during 70 min prior to analysis with a dedicated
reversed-phase column (Waters, Milford, MA, US). The
variability of this amino acid analytical method is of 10%
except in the case of cysteine for which the standard
deviation is of 20%.
Depending on the cultivation mode, the specific rates
of cell growth (μ), glucose and glutamine consumption
(νGlc, νGln) and lactate or ammonia production (qLac,
qNH3) were calculated using the following equations.
Metabolic yields were then calculated to evaluate the
efficiency of each culture mode in term of cell metabolic
state.
Batch:
μ =
(
Xt+1 − Xt−1
2× Xt
)
ν =
(St−1 − St+1)
Xt
π =
(Pt+1 − Pt−1)
Xt
Perfusion:
μ =
(
Xt+1 − Xt−1
2× Xt
)
ν =
(St−1 − St+1) + (S0 − St)×Q
Xt
π =
(Pt+1 − Pt−1) + Pt ×Q
Xt
YP/X =
π
μ
YS/X =
ν
μ
YP/S =
π
ν
X: cell density
S: concentration of substrates, mM
P: concentration of products, mM
t: cultivation time
Q: perfusion rate
Considering these equations and applying the follow-
ing equations, it was possible to provide variability
values on the metabolic yields calculated.
with c = a/b ; so
c
c
=
a
a
+
b
b
Virus quantification
TCID50 assays
Infectious viral particles were quantified by the same
method as described by Le Ru et al.(2010) [12]. MDCK
cells were cultured in EMEM supplemented with 10%
FBS in 96-well plates at a seeding cell density of 2.8 ×
104 cells/well. Cells were infected with serial dilutions of
culture supernatant after being washed twice with PBS.
Supernatant dilutions were performed in 96-well plates
with a 5-fold ratio of EMEM medium containing TPCK
trypsin (1 μg/mL) at 35°C. TCID50 titers were then
evaluated either from microscopic visual detection of
plaques assays after 7 days [42] or from microscopic
detection of HA protein with antibody fluorescent label-
ing after two days post-infection [49]. TCID50 titers
were then calculated according to the method of Spear-
man-Karber [50]. Infectious titers that were calculated
from the TCID50 assay were expressed as infectious
viral particle per mL (IVP/mL). The standard deviation
obtained for this assay was 0.5 logTCID50 units/mL.
Hemagglutination assay
HA sample contents were quantified by hemagglutina-
tion assay using chicken red blood cells, set at 2.0 × 107
cell/mL. The assays were performed using the protocol
described by Genzel et al. (2007) [49]. The standard
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deviation determined for this assay was of 0.18 log HA
units/mL.
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